Emergence Therapeutics
Key Facts
| Invested since | 2019 |
| Based in | Duisburg |
About the company
Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat.
Problem: Solid cancers are still very difficult to treat. Most treatments increase life expectancy, but only a few lead to a complete cure. Antibody drug conjugates (ADCs) have proven to be a promising therapeutic approach, but still cause significant and toxic side effects. The solution: Emergence Therapeutics has identified several areas where ADCs can be improved. These are the antibody itself, the toxin used to kill the cancer cell, and the linker that couples the toxin to the antibody.
Do you want to
know more about this company?
Emergence Therapeutics in the news
More startups from Life Sciences
Exit
The core competency of AQ Implants GmbH is the endoprosthetic reconstruction of severe and complex defects and anomalies. With the development of innovative implant systems AQ Implants GmbH provides surgeons …
to AQ Implants
Nebula Biocides GmbH was founded in 2019 as a spin-off from the Leibniz Institute for Plasma Science and Technology (INP) by the scientists Dr. Jörn Winter, Dr. Ansgar Schmidt-Bleker and …
to Nebula Biocides
CustomSurg, founded in 2021, is a Spin-Off from ETH Zurich and Harvard University. The company is developing software-as-a-medical-device (SaMD) solutions for the optimal selection and placement of orthopaedic implants in …
to CustomSurg
TECregen is pioneering thymus rejuvenation to address conditions driven by impaired T-cell responses. The company’s innovative approach focuses on revitalizing and expanding thymic epithelial cells (TECs) to replenish T cells …
to TECregen
Exit
ChromoTek focuses on the discovery and development of innovative fluorescent nanoprobes derived from single-chain antibodies from Camelidae (Chromobodies) for applications in research and high-content screening.
to ChromoTek
MDTB stands for drugs, which are based on the immunomodulating drug substance Desacell®. Desacell® is an advanced drug platform based on MSC (Mesenchymal Stromal Cells) and addresses many inflammatory-associated diseases …
to MDTB Cell Manufacturing
Inovedis is developing a new surgical technique for rotator cuff ruptures based on a PEEK implant. This injury is by so far the most typical shoulder injury. The patented SINEFIX …
to Inovedis
C-mo Medical Solutions is an award-winning Digital Health start-up that develops solutions for the diagnosis and management of cough-incident medical conditions. The company’s mission is to unravel the clinical potential …
to C-mo
Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular …
to HepaRegeniX
miRdetect is a biotechnology company founded in 2016, with the aim to revolutionise cancer diagnostics. The focus is on development, production and distribution of in-vitro diagnostics based on molecular diagnostic …
to miRdetect
Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. …
to Synendos Therapeuthics
Carelane is a health tech startup focused on addressing the inefficiencies in clinical trials by integrating multiple essential functions into a single, streamlined system, thereby digitizing study protocols and processes. …
to Carelane